转移中的线粒体核糖体蛋白及其作为预后和治疗靶点的潜力。

IF 7.7 2区 医学 Q1 ONCOLOGY
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-10-01 DOI:10.1007/s10555-024-10216-4
Jasmine M Bacon, Johanna L Jones, Guei-Sheung Liu, Joanne L Dickinson, Kelsie Raspin
{"title":"转移中的线粒体核糖体蛋白及其作为预后和治疗靶点的潜力。","authors":"Jasmine M Bacon, Johanna L Jones, Guei-Sheung Liu, Joanne L Dickinson, Kelsie Raspin","doi":"10.1007/s10555-024-10216-4","DOIUrl":null,"url":null,"abstract":"<p><p>The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1119-1135"},"PeriodicalIF":7.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554709/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets.\",\"authors\":\"Jasmine M Bacon, Johanna L Jones, Guei-Sheung Liu, Joanne L Dickinson, Kelsie Raspin\",\"doi\":\"10.1007/s10555-024-10216-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.</p>\",\"PeriodicalId\":9489,\"journal\":{\"name\":\"Cancer and Metastasis Reviews\",\"volume\":\" \",\"pages\":\"1119-1135\"},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554709/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer and Metastasis Reviews\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1007/s10555-024-10216-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and Metastasis Reviews","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1007/s10555-024-10216-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

线粒体是一种重要的细胞器,被称为细胞的动力室。线粒体核糖体蛋白(MRPs)由核编码,在细胞质中合成,但在线粒体中发挥主要功能,包括翻译、转录、细胞死亡和维持。然而,MRPs 也与癌症有关,特别是与多种癌症类型的晚期疾病和转移有关,它们在细胞存活和进展中发挥着核心作用。对于某些癌症,它们的表达改变已被研究为潜在的预后标志物和/或治疗靶点,这也是本综述的重点。目前,美国食品和药物管理局以及欧洲药品管理局已批准将几种针对 MRPs 的疗法用于其他疾病,这为将其重新用于晚期和转移性癌症提供了机会。在此,我们回顾了支持关键 MRPs 作为多种癌症晚期疾病分子驱动因素的证据。我们还强调了未来将 MRPs 作为精准靶点用于治疗晚期癌症的前景广阔的途径,目前对晚期癌症的有效治疗方案非常有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets.

The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
17.00
自引率
0.00%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Contemporary biomedical research is on the threshold of an era in which physiological and pathological processes can be analyzed in increasingly precise and mechanistic terms.The transformation of biology from a largely descriptive, phenomenological discipline to one in which the regulatory principles can be understood and manipulated with predictability brings a new dimension to the study of cancer and the search for effective therapeutic modalities for this disease. Cancer and Metastasis Reviews provides a forum for critical review and discussion of these challenging developments. A major function of the journal is to review some of the more important and interesting recent developments in the biology and treatment of malignant disease, as well as to highlight new and promising directions, be they technological or conceptual. Contributors are encouraged to review their personal work and be speculative.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信